{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:42:35Z","timestamp":1792086155300,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82303841"],"award-info":[{"award-number":["82303841"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Youth Science Foundation B of Hunan Province","award":["2025JJ40071"],"award-info":[{"award-number":["2025JJ40071"]}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2023JJ40800"],"award-info":[{"award-number":["2023JJ40800"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2023JJ40975"],"award-info":[{"award-number":["2023JJ40975"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Central South University Innovation-Driven Research Programme","award":["2023CXQD075"],"award-info":[{"award-number":["2023CXQD075"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13361-0","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T21:44:14Z","timestamp":1753739054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immune infiltration related PRDX4 facilitates the malignant features and drug resistance of breast cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Wenying","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maonan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"13361_CR1","doi-asserted-by":"publisher","first-page":"105828","DOI":"10.1016\/j.ebiom.2025.105828","volume":"118","author":"MR Lloyd","year":"2025","unstructured":"Lloyd, M. R. et al. A bedside-to-bench translational analysis of NF1 alterations and CDK4\/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer. EBioMedicine 118, 105828 (2025).","journal-title":"EBioMedicine"},{"key":"13361_CR2","doi-asserted-by":"crossref","unstructured":"Zeng, X. et al. Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop. J. Clin. Invest 135, (2025).","DOI":"10.1172\/JCI188120"},{"key":"13361_CR3","first-page":"400","volume":"49","author":"WT Yang","year":"2020","unstructured":"Yang, W. T. & Bu, H. [Updates in the 5(th) edition of WHO classification of tumours of the breast. Zhonghua Bing Li Xue Za Zhi. 49, 400\u2013405 (2020).","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"13361_CR4","doi-asserted-by":"crossref","unstructured":"Prajzendanc, K. DCIS progression and the tumor microenvironment: molecular insights and prognostic challenges. Cancers (Basel) 17, (2025).","DOI":"10.3390\/cancers17121925"},{"key":"13361_CR5","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/cac2.12197","volume":"41","author":"H Qiu","year":"2021","unstructured":"Qiu, H., Cao, S. & Xu, R. Cancer incidence, mortality, and burden in china: a time-trend analysis and comparison with the United States and united Kingdom based on the global epidemiological data released in 2020. Cancer Commun. (Lond). 41, 1037\u20131048 (2021).","journal-title":"Cancer Commun. (Lond)"},{"key":"13361_CR6","unstructured":"Collaborators, G. B. D. V. C. Global, regional, and National trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the global burden of disease study 2023. Lancet (2025)."},{"key":"13361_CR7","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1038\/s41467-025-59144-z","volume":"16","author":"GJ Thorn","year":"2025","unstructured":"Thorn, G. J. et al. The clinical and molecular landscape of breast cancer in women of African and South Asian ancestry. Nat. Commun. 16, 4237 (2025).","journal-title":"Nat. Commun."},{"key":"13361_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.tibs.2015.05.001","volume":"40","author":"A Perkins","year":"2015","unstructured":"Perkins, A., Nelson, K. J., Parsonage, D., Poole, L. B. & Karplus, P. A. Peroxiredoxins: guardians against oxidative stress and modulators of peroxide signaling. Trends Biochem. Sci. 40, 435\u2013445 (2015).","journal-title":"Trends Biochem. Sci."},{"key":"13361_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/jcmm.12955","volume":"21","author":"C Ding","year":"2017","unstructured":"Ding, C., Fan, X. & Wu, G. Peroxiredoxin 1 - an antioxidant enzyme in cancer. J. Cell. Mol. Med. 21, 193\u2013202 (2017).","journal-title":"J. Cell. Mol. Med."},{"key":"13361_CR10","doi-asserted-by":"publisher","first-page":"10290","DOI":"10.7150\/thno.46728","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Celastrol induces ROS-mediated apoptosis via directly targeting peroxiredoxin-2 in gastric cancer cells. Theranostics 10, 10290\u201310308 (2020).","journal-title":"Theranostics"},{"key":"13361_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.chembiol.2023.02.003","volume":"30","author":"C Lv","year":"2023","unstructured":"Lv, C. et al. Ainsliadimer A induces ROS-mediated apoptosis in colorectal cancer cells via directly targeting Peroxiredoxin 1 and 2. Cell. Chem. Biol. 30, 295\u2013307.e295 (2023).","journal-title":"Cell. Chem. Biol."},{"key":"13361_CR12","first-page":"832","volume":"29","author":"B Qiao","year":"2012","unstructured":"Qiao, B. et al. Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach. Int. J. Mol. Med. 29, 832\u2013840 (2012).","journal-title":"Int. J. Mol. Med."},{"key":"13361_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.23736\/S0031-0808.20.03978-6","volume":"65","author":"C Song","year":"2023","unstructured":"Song, C. et al. PRDX1 stimulates non-small-cell lung carcinoma to proliferate via the Wnt\/beta-Catenin signaling. Panminerva Med. 65, 37\u201342 (2023).","journal-title":"Panminerva Med."},{"key":"13361_CR14","doi-asserted-by":"publisher","first-page":"e42818","DOI":"10.1371\/journal.pone.0042818","volume":"7","author":"TH Kim","year":"2012","unstructured":"Kim, T. H. et al. Suppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth. PLoS One. 7, e42818 (2012).","journal-title":"PLoS One"},{"key":"13361_CR15","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1021\/pr201172n","volume":"11","author":"R Ummanni","year":"2012","unstructured":"Ummanni, R. et al. Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. J. Proteome Res. 11, 2452\u20132466 (2012).","journal-title":"J. Proteome Res."},{"key":"13361_CR16","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1038\/s41467-022-34654-2","volume":"13","author":"A Vdovin","year":"2022","unstructured":"Vdovin, A. et al. The deubiquitinase OTUD1 regulates Immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma. Nat. Commun. 13, 6820 (2022).","journal-title":"Nat. Commun."},{"key":"13361_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12032-023-02265-6","volume":"41","author":"P Lei","year":"2024","unstructured":"Lei, P. et al. Exploring the role of PRDX4 in the development of uterine corpus endometrial carcinoma. Med. Oncol. 41, 48 (2024).","journal-title":"Med. Oncol."},{"key":"13361_CR18","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1093\/nar\/gkv873","volume":"44","author":"Z Ji","year":"2016","unstructured":"Ji, Z., Vokes, S. A., Dang, C. V. & Ji, H. Turning publicly available gene expression data into discoveries using gene set context analysis. Nucleic Acids Res. 44, e8 (2016).","journal-title":"Nucleic Acids Res."},{"key":"13361_CR19","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1002\/pmic.201500409","volume":"16","author":"S Navani","year":"2016","unstructured":"Navani, S. Manual evaluation of tissue microarrays in a high-throughput research project: the contribution of Indian surgical pathology to the human protein atlas (HPA) project. Proteomics 16, 1266\u20131270 (2016).","journal-title":"Proteomics"},{"key":"13361_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar, D. S. et al. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19, 649\u2013658 (2017).","journal-title":"Neoplasia"},{"key":"13361_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov"},{"key":"13361_CR22","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"13361_CR23","doi-asserted-by":"publisher","first-page":"D1420","DOI":"10.1093\/nar\/gkaa1020","volume":"49","author":"D Sun","year":"2021","unstructured":"Sun, D. et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 49, D1420\u2013D1430 (2021).","journal-title":"Nucleic Acids Res."},{"key":"13361_CR24","doi-asserted-by":"publisher","first-page":"D900","DOI":"10.1093\/nar\/gky939","volume":"47","author":"H Yuan","year":"2019","unstructured":"Yuan, H. et al. CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 47, D900\u2013D908 (2019).","journal-title":"Nucleic Acids Res."},{"key":"13361_CR25","doi-asserted-by":"publisher","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","volume":"49","author":"S Kim","year":"2021","unstructured":"Kim, S. et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 49, D1388\u2013D1395 (2021).","journal-title":"Nucleic Acids Res."},{"key":"13361_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/pro.4213","volume":"31","author":"SK Burley","year":"2022","unstructured":"Burley, S. K. et al. Celebrating 50 years of the PDB with new tools for understanding and visualizing biological macromolecules in 3D. Protein Sci. 31, 187\u2013208 (2022).","journal-title":"Protein Sci."},{"key":"13361_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-1-4939-9752-7_9","volume":"2053","author":"G Bitencourt-Ferreira","year":"2019","unstructured":"Bitencourt-Ferreira, G., Pintro, V. O. & de Azevedo, W. F. Jr. Docking with AutoDock4. Methods Mol. Biol. 2053, 125\u2013148 (2019).","journal-title":"Methods Mol. Biol."},{"key":"13361_CR28","doi-asserted-by":"publisher","first-page":"W530","DOI":"10.1093\/nar\/gkab294","volume":"49","author":"MF Adasme","year":"2021","unstructured":"Adasme, M. F. et al. PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 49, W530\u2013W534 (2021).","journal-title":"Nucleic Acids Res."},{"key":"13361_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"NM O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle, N. M. et al. Open babel: an open chemical toolbox. J. Cheminform. 3, 33 (2011).","journal-title":"J. Cheminform"},{"key":"13361_CR30","doi-asserted-by":"publisher","first-page":"167017","DOI":"10.1016\/j.bbadis.2024.167017","volume":"1870","author":"Z Feng","year":"2024","unstructured":"Feng, Z. et al. Immune infiltration related CENPI associates with the malignant features and drug resistance of lung adenocarcinoma. Biochim. Biophys. Acta Mol. Basis Dis. 1870, 167017 (2024).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"13361_CR31","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"13361_CR32","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1097\/RLU.0000000000003678","volume":"46","author":"N Jokar","year":"2021","unstructured":"Jokar, N. et al. Theranostic approach in breast cancer: A treasured tailor for future oncology. Clin. Nucl. Med. 46, e410\u2013e420 (2021).","journal-title":"Clin. Nucl. Med."},{"key":"13361_CR33","doi-asserted-by":"crossref","unstructured":"Jain, P. et al. NOX4 links metabolic regulation in pancreatic cancer to Endoplasmic reticulum redox vulnerability and dependence on PRDX4. Sci. Adv. 7, (2021).","DOI":"10.1126\/sciadv.abf7114"},{"key":"13361_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","volume":"22","author":"SJ Vervoort","year":"2022","unstructured":"Vervoort, S. J. et al. Targeting transcription cycles in cancer. Nat. Rev. Cancer. 22, 5\u201324 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"13361_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1756-9966-28-93","volume":"28","author":"MK Cha","year":"2009","unstructured":"Cha, M. K., Suh, K. H. & Kim, I. H. Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J. Exp. Clin. Cancer Res. 28, 93 (2009).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"13361_CR36","doi-asserted-by":"crossref","unstructured":"Fei, L. et al. PT(f)-SRiApt targeting SCAF4-POLR2A interaction suppresses tumor growth and promotes antitumor immunity in triple-negative breast cancer. Adv. Sci. (Weinh) e00433 (2025).","DOI":"10.1002\/advs.202500433"},{"key":"13361_CR37","doi-asserted-by":"publisher","first-page":"eadr1728","DOI":"10.1126\/sciadv.adr1728","volume":"11","author":"J Zhao","year":"2025","unstructured":"Zhao, J., Tong, A., Liu, J., Xu, M. & Mi, P. Tumor-targeting nanocarriers amplified immunotherapy of cold tumors by STING activation and inhibiting immune evasion. Sci. Adv. 11, eadr1728 (2025).","journal-title":"Sci. Adv."},{"key":"13361_CR38","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jare.2024.06.029","volume":"72","author":"Y Luo","year":"2025","unstructured":"Luo, Y. et al. RNA modification gene WDR4 facilitates tumor progression and immunotherapy resistance in breast cancer. J. Adv. Res. 72, 333\u2013351 (2025).","journal-title":"J. Adv. Res."},{"key":"13361_CR39","first-page":"270009","volume":"5","author":"F Xia","year":"2025","unstructured":"Xia, F. et al. Cancer immunotherapy based on the bidirectional reprogramming of the tumor microenvironment by a brakes off\/ step on the accelerator Core-Shell manganese Phosphate\/siPD-L1 modulator. Explor. (Beijing). 5, 270009 (2025).","journal-title":"Explor. (Beijing)"},{"key":"13361_CR40","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.chembiol.2019.04.003","volume":"26","author":"H Zhu","year":"2019","unstructured":"Zhu, H. et al. Parvifoline AA promotes susceptibility of hepatocarcinoma to natural killer cell-mediated cytolysis by targeting Peroxiredoxin. Cell. Chem. Biol. 26, 1122\u20131132e1126 (2019).","journal-title":"Cell. Chem. Biol."},{"key":"13361_CR41","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/j.jid.2021.04.015","volume":"141","author":"R Yamaguchi","year":"2021","unstructured":"Yamaguchi, R. et al. PRDX4 improved aging-related delayed wound healing in mice. J. Invest. Dermatol. 141, 2720\u20132729 (2021).","journal-title":"J. Invest. Dermatol."},{"key":"13361_CR42","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1089\/ars.2017.7422","volume":"28","author":"MB Hampton","year":"2018","unstructured":"Hampton, M. B., Vick, K. A., Skoko, J. J. & Neumann, C. A. Peroxiredoxin involvement in the initiation and progression of human cancer. Antioxid. Redox Signal. 28, 591\u2013608 (2018).","journal-title":"Antioxid. Redox Signal."},{"key":"13361_CR43","doi-asserted-by":"publisher","first-page":"150522","DOI":"10.1016\/j.bbrc.2024.150522","volume":"738","author":"YY Hao","year":"2024","unstructured":"Hao, Y. Y. et al. Peroxiredoxin 1 modulates oxidative stress resistance and cell apoptosis through stemness in liver cancer under non-thermal plasma treatment. Biochem. Biophys. Res. Commun. 738, 150522 (2024).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"13361_CR44","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/ijc.34999","volume":"155","author":"Y Shen","year":"2024","unstructured":"Shen, Y., You, Z., Li, L., Tang, X. & Shan, X. The interaction of PRDX1 with Cofilin promotes oral squamous cell carcinoma metastasis. Int. J. Cancer. 155, 1290\u20131302 (2024).","journal-title":"Int. J. Cancer"},{"key":"13361_CR45","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1158\/1535-7163.MCT-09-0904","volume":"9","author":"JN Ho","year":"2010","unstructured":"Ho, J. N. et al. Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells. Mol. Cancer Ther. 9, 825\u2013832 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"13361_CR46","doi-asserted-by":"crossref","unstructured":"Huang, C. Y. et al. 2D-DIGE-MS proteomics approaches for identification of Gelsolin and Peroxiredoxin 4 with lymph node metastasis in colorectal cancer. Cancers (Basel).14, (2022).","DOI":"10.3390\/cancers14133189"},{"key":"13361_CR47","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s13402-019-00460-0","volume":"42","author":"W Wang","year":"2019","unstructured":"Wang, W. et al. Peroxiredoxin 4 suppresses anoikis and augments growth and metastasis of hepatocellular carcinoma cells through the beta-catenin\/ID2 pathway. Cell. Oncol. (Dordr. 42, 769\u2013781 (2019).","journal-title":"Cell. Oncol. (Dordr"},{"key":"13361_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12943-023-01804-z","volume":"22","author":"M Jiang","year":"2023","unstructured":"Jiang, M. et al. Exosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1. Mol. Cancer. 22, 113 (2023).","journal-title":"Mol. Cancer"},{"key":"13361_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-020-0149-3","volume":"5","author":"P Chen","year":"2020","unstructured":"Chen, P. et al. Erianin, a novel dibenzyl compound in dendrobium extract, inhibits lung cancer cell growth and migration via calcium\/calmodulin-dependent ferroptosis. Signal. Transduct. Target. Ther. 5, 51 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"13361_CR50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-021-01223-x","volume":"15","author":"H Li","year":"2022","unstructured":"Li, H. et al. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk. J. Hematol. Oncol. 15, 2 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"13361_CR51","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.apsb.2021.12.007","volume":"12","author":"P Luo","year":"2022","unstructured":"Luo, P. et al. Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1. Acta Pharm. Sin B. 12, 2300\u20132314 (2022).","journal-title":"Acta Pharm. Sin B"},{"key":"13361_CR52","first-page":"5590","volume":"13","author":"B Quan","year":"2023","unstructured":"Quan, B. et al. LINC02362\/hsa-miR-18a-5p\/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma. Am. J. Cancer Res. 13, 5590\u20135609 (2023).","journal-title":"Am. J. Cancer Res."},{"key":"13361_CR53","doi-asserted-by":"publisher","first-page":"1115510","DOI":"10.3389\/fonc.2023.1115510","volume":"13","author":"X Zhu","year":"2023","unstructured":"Zhu, X. et al. ITGB1-mediated molecular landscape and cuproptosis phenotype induced the worse prognosis in diffuse gastric cancer. Front. Oncol. 13, 1115510 (2023).","journal-title":"Front. Oncol."},{"key":"13361_CR54","doi-asserted-by":"publisher","first-page":"eadk9944","DOI":"10.1126\/sciadv.adk9944","volume":"10","author":"H Maldonado","year":"2024","unstructured":"Maldonado, H. et al. A trafficking regulatory subnetwork governs alpha(V)beta(6) integrin-HER2 cross-talk to control breast cancer invasion and drug resistance. Sci. Adv. 10, eadk9944 (2024).","journal-title":"Sci. Adv."},{"key":"13361_CR55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/2159-8290.CD-22-0475","volume":"13","author":"SS Onkar","year":"2023","unstructured":"Onkar, S. S. et al. The great immune escape: understanding the divergent immune response in breast cancer subtypes. Cancer Discov. 13, 23\u201340 (2023).","journal-title":"Cancer Discov"},{"key":"13361_CR56","doi-asserted-by":"crossref","unstructured":"Hu, D. et al. p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2(+) breast cancer that limits trastuzumab deruxtecan efficacy. Nat. Cancer. (2025).","DOI":"10.1038\/s43018-025-00969-4"},{"key":"13361_CR57","doi-asserted-by":"publisher","first-page":"217112","DOI":"10.1016\/j.canlet.2024.217112","volume":"598","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. Cancer Lett. 598, 217112 (2024).","journal-title":"Cancer Lett."},{"key":"13361_CR58","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.freeradbiomed.2024.12.015","volume":"227","author":"J Fujii","year":"2025","unstructured":"Fujii, J., Ochi, H. & Yamada, S. A comprehensive review of peroxiredoxin 4, a redox protein evolved in oxidative protein folding coupled with hydrogen peroxide detoxification. Free Radic Biol. Med. 227, 336\u2013354 (2025).","journal-title":"Free Radic Biol. Med."},{"key":"13361_CR59","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.ccell.2021.06.001","volume":"39","author":"AB Hanker","year":"2021","unstructured":"Hanker, A. B. et al. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2\/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell. 39, 1099\u20131114 (2021). e1098.","journal-title":"Cancer Cell."},{"key":"13361_CR60","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.annonc.2024.07.245","volume":"35","author":"RA Freedman","year":"2024","unstructured":"Freedman, R. A. et al. Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: translational breast cancer research consortium trial 022. Ann. Oncol. 35, 993\u20131002 (2024).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13361-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:02:07Z","timestamp":1757314927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13361-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13361"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13361-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was carried out using the opt-out method for the case series of our hospital. We have confirmed that all experiments were conducted in accordance with the relevant guidelines and regulations. This study was approved by the Ethics Committee of Xiangya Hospital (Approval No. 202401013) and was conducted in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was waived by our Institutional Review Board (Medical Ethics Committee of Xiangya Hospital, Central South University) because of the retrospective nature of our study. Research still conducts to comply with ethical norms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27507"}}